Sonia Franciosi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4591525/publications.pdf

Version: 2024-02-01

623734 501196 32 836 14 28 citations h-index g-index papers 33 33 33 1416 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2012, 45, 438-449.	4.4	105
2	The role of the autonomic nervous system in arrhythmias and sudden cardiac death. Autonomic Neuroscience: Basic and Clinical, 2017, 205, 1-11.	2.8	104
3	IL-8 enhancement of amyloid-beta (A \hat{l}^2 1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. Journal of Neuroimmunology, 2005, 159, 66-74.	2.3	82
4	Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2015, 76, 46-56.	4.4	78
5	Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Scientific Reports, 2016, 6, 31652.	3.3	59
6	Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiology of Disease, 2015, 76, 24-36.	4.4	48
7	A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Human Molecular Genetics, 2015, 24, 2604-2614.	2.9	48
8	Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathologica Communications, 2018, 6, 16.	5.2	47
9	SCN5A mutations in 442 neonates and children: genotype–phenotype correlation and identification of higher-risk subgroups. European Heart Journal, 2018, 39, 2879-2887.	2.2	33
10	Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiology, 2022, 7, 84.	6.1	28
11	An International Multicenter Cohort Study on Î ² -Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2022, 145, 333-344.	1.6	28
12	Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. BMC Biology, 2016, 14, 108.	3.8	22
13	Initially unexplained cardiac arrest in children and adolescents: A national experience from the Canadian Pediatric Heart Rhythm Network. Heart Rhythm, 2020, 17, 975-981.	0.7	21
14	Burst Exercise Testing Can Unmask Arrhythmias in Patients With Incompletely Penetrant Catecholaminergic Polymorphic Ventricular Tachycardia. JACC: Clinical Electrophysiology, 2021, 7, 437-441.	3.2	18
15	Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nature Communications, 2013, 4, 2906.	12.8	15
16	The Safety and Effectiveness of Flecainide in Children in the Current Era. Pediatric Cardiology, 2017, 38, 1633-1638.	1.3	14
17	Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2021, 18, 1825-1832.	0.7	13
18	Chronotropic incompetence as a risk predictor in children and young adults with catecholaminergic polymorphic ventricular tachycardia. Journal of Cardiovascular Electrophysiology, 2019, 30, 1923-1929.	1.7	11

#	Article	IF	CITATIONS
19	Potential overdiagnosis of long QT syndrome using exercise stress and QT stand testing in children and adolescents with a low probability of disease. Journal of Cardiovascular Electrophysiology, 2021, 32, 500-506.	1.7	10
20	A systematic review and metaâ€analysis of clinical variables used in Huntington disease research. Movement Disorders, 2013, 28, 1987-1994.	3.9	8
21	Age-related mitochondrial alterations in brain and skeletal muscle of the YAC128 model of Huntington disease. Npj Aging and Mechanisms of Disease, 2021, 7, 26.	4.5	8
22	Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Journal of Huntington's Disease, 2012, 1, 243-260.	1.9	7
23	Potential Role of Life Stress in Unexplained Sudden Cardiac Arrest. CJC Open, 2021, 3, 285-291.	1.5	7
24	Pediatric Catecholaminergic Polymorphic Ventricular Tachycardia: A Translational Perspective for the Clinician-Scientist. International Journal of Molecular Sciences, 2021, 22, 9293.	4.1	7
25	The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study. Journal of Community Genetics, 2018, 9, 257-262.	1.2	5
26	p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease. Neuroscience, 2017, 352, 79-87.	2.3	3
27	Intermediate-coupled premature ventricular complexes and ventricular tachycardia during exercise recovery. HeartRhythm Case Reports, 2021, 7, 127-130.	0.4	3
28	Polymorphic ventricular tachycardia associated with an episode of reflex syncope: Is this the needle in the haystack?. HeartRhythm Case Reports, 2018, 4, 510-513.	0.4	2
29	Paediatric supraventricular tachycardia patients potentially more at risk of developing psychological difficulties compared to healthy peers. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 1017-1024.	1.5	1
30	Sudden Cardiac Arrest in the Paediatric Population. , 2022, 1, 45-59.		1
31	L8 Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A92.3-A93.	1.9	0
32	Dynamic Electrocardiographic Abnormalities Captured in TimothyÂSyndrome. JACC: Clinical Electrophysiology, 2018, 4, 1486-1487.	3.2	0